Andrea Amorosi
Overview
Explore the profile of Andrea Amorosi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loscocco G, Vannucchi M, Santi R, Amorosi A, Scarpino S, Siciliano M, et al.
Pathol Res Pract
. 2024 Oct;
263:155648.
PMID: 39405803
Hepatoid thymic carcinoma (HTC) is an extremely rare variant of primary epithelial tumor of the thymus morphologically resembling hepatocellular carcinoma Herein, we report an additional case of HTC diagnosed in...
2.
Ambrosio M, Spagnoli L, Perotti B, Petrelli F, Caini S, Saieva C, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672387
Introduction: Published evidence suggests that immunonutrition has the potential to decrease postoperative complications and reduce length of stay in patients undergoing surgery for colorectal cancer. However, only a few studies...
3.
Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
Crupi F, Sordi B, Vanderwert F, Gesullo F, Amorosi A, Mannelli F, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955907
The diagnosis of systemic mastocytosis (SM) is based on various clinical, dermatological, serological, and hematological findings but essentially relies on histological evidence of an abnormal increase in tissue-localized mast cells...
4.
Roviello G, Catalano M, Santi R, Santoni M, Galli I, Amorosi A, et al.
Front Oncol
. 2022 Aug;
12:912699.
PMID: 35936721
Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as muscle invasive in 25% of cases. Although several studies have demonstrated an overall 5% absolute...
5.
Petrelli F, Fratini G, Sbrozzi-Vanni A, Giusti A, Manta R, Vignali C, et al.
World J Gastroenterol
. 2022 Jul;
28(21):2396-2402.
PMID: 35800185
We described the case of a peripancreatic paraganglioma (PGL) misdiagnosed as pancreatic lesion. Surgical exploration revealed an unremarkable pancreas and a large well-defined cystic mass originating at the mesocolon root....
6.
Tonelli F, Di Martino C, Amorosi A, Mini E, Nesi G
Updates Surg
. 2022 Feb;
74(2):637-647.
PMID: 35217982
Patients with ulcerative colitis (UC) are at risk of developing a colorectal cancer. The aim of this study was to examine our experience in the treatment of ulcerative Colitis Cancer...
7.
Di Vito A, Donato A, Presta I, Mancuso T, Brunetti F, Mastroroberto P, et al.
Int J Mol Sci
. 2021 Jan;
22(2).
PMID: 33477599
Calcific Aortic Valve Disease (CAVD) is the most common valvular heart disease in developed countries and in the ageing population. It is strongly correlated to median age, affecting up to...
8.
Sabatino J, De Rosa S, Tamme L, Iaconetti C, Sorrentino S, Polimeni A, et al.
Cardiovasc Diabetol
. 2020 May;
19(1):66.
PMID: 32414364
Background: Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover, the EMPA-REG OUTCOME trial demonstrated a 14%...
9.
Nesi G, Galli I, Amorosi A, Santi R
Pol J Pathol
. 2019 Sep;
70(1):21-25.
PMID: 31556547
Our understanding of aetiological factors associated with urinary bladder cancer has radically improved over the last decades. Cigarette smoking is considered the most important risk factor, even in the industrialised...
10.
Mignogna C, Amorosi A, Maselli D, Santise G
Int J Surg Pathol
. 2019 May;
28(1):78-79.
PMID: 31068037
No abstract available.